Primary Progressive Multiple Sclerosis
Conditions
Brief summary
The goal of this non-interventional, observational study is to determine whether cortical pathology can be slowed down by use of ocrelizumab.
Detailed description
To study the effect of ocrelizumab on cortical lesion accumulation in patients with primary-progressive multiple sclerosis participating in the ORATORIO: a post-hoc analysis of a double-blind, randomized, phase 3, placebo-controlled study.
Interventions
OTHEROcrelizumab
Non-interventional
Sponsors
Genentech, Inc.
State University of New York at Buffalo
Study design
Observational model
CASE_ONLY
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patient participating in the ORATORIO study * MRI scans available at baseline * Presence of T2-weighted image (WI) (FLAIR, T2/PD), and 2D/3D T1-WI at baseline
Exclusion criteria
\- None
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Cortical lesion number accumulation | 5 years | Cortical lesion accumulation as measured using MRI between subjects on placebo and subjects who took ocrelizumab. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Cortical lesion number accumulation and disability. | 5 years | Cortical lesion number accumulation as measured by MRI for subjects who developed disability over the course of the placebo-controlled phase of the study. |
Countries
United States
Outcome results
None listed